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Abstract: Background: Prostate Cancer is recognized as the second cause of death due to cancers among men worldwide.
Due to the lack of local evidence on the survival rate of patients with prostate cancer, this study aimed to esti-
mate the 5-year survival rate of patients afflicted with this condition in Iran. Materials and Methods: This study
made use of information on 9,772 prostate cancer cases who were registered in the National Cancer Registry
during 2010-15. A telephone survey, with a response rate of 35%, was conducted to gather additional informa-
tion such as death status, demographic characteristics, and clinical profile. Kaplan-Meier estimates was used to
estimate five-year survival rates. Results: The overall five-year survival rate of prostate cancer was 82% (95% CI:
80-83%). Significantly higher five-year survival rates were observed among retired patients (rate: 94%,95%CI:
92-96), patients receiving a combination of radiotherapy and surgery (rate: 92%,95%CI: 89-94), and patients re-
siding in rural areas (rate: 92%, 95%CI: 90-93). Conclusion: We found that various factors such as occupation,
area of residence, and the type of medication, may influence on survival rate of prostate cancer. Careful evalua-
tion and understanding of effective factors are required to adopt proper health policies and treatment options.
Due to the importance of etiologic and epidemiological data, inclusion of such data into the national registry
system for Prostate Cancer is strongly recommended.
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1. Introduction
Nowadays, Prostate Cancer (PCa) is recognized as the most
common non-skin cancer and the second cause of death due
to cancers among men (1, 2). PCa accounts for nearly 12%
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of all new cancer cases, and approximately 10% of all male
cancers (3, 4). The estimated incidence rate of PCa varies
among different geographic areas, with the highest in devel-
oped countries such as the United States (118.2 per 100,000
population) and the lowest in developing countries such as
India (4.4 per 100,000 population) (5, 6). However, the ob-
served difference is subject to bias due to the application of
different early detection strategies, such as screening pro-
grams on Prostate-Specific Antigen (PSA), and varying de-
grees of accuracy in cancer registration system. On the other
hand, potential well-known factors, such as diet, lifestyle,
smoking habits, physical activity, ethnicity, and environmen-
tal exposure, can also partially explain the observed differ-
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ence in the occurrence of prostate cancer (3, 7-14). Overall,
evidence suggests that the global incidence of prostate can-
cer is increasing (15, 16). Iran is a developing Middle Eastern
country with low prevalence of PCa. Previous studies on Ira-
nian population have shown that prostate cancer was ranked
the sixth among all cancers and the third among male can-
cers. Similar to other parts of the world, incidence of PCa is
on the rise in Iran. In fact, the age-standardized incidence
rate has increased from 5.4 per 100,000 in 2003 to 12.6 per
100,000 in 2012. Considering this rising trend, it is expected
that PCa will become a major public health concern in near
future in Iran (17-21).
Since the 19th century, various treatments, including
Androgen-ablation therapy, prostatectomy, radiation ther-
apy, and chemotherapy, have been used. With the advances
of these methods over the years, they have formed the ba-
sis of prostate cancer treatment. Once the diagnosis is con-
firmed, clinicians determine the treatment strategy based on
clinical conditions, patient’s preference, and possible side ef-
fects, to improve survival and prognosis (20, 22-24). With
a wider access to Prostate-Specific Antigen (PSA) test, the
number of patients diagnosed in the early stages of prostate
cancer has increased. In saying that, due to the increasing
trend in the incidence of such condition, it is regarded as a
major health issue in different societies, including Iran (25,
26). Study of survival and related factors in patients with
prostate cancer has a paramount importance as it helps cre-
ate more valid evidence for health policymakers. This, in re-
turn, allows for more efficient treatments. Nevertheless, the
current knowledge on the prognosis and survival of prostate
cancer in Iran is limited and incomplete. This article used
national cancer-registry data to provide valid information on
survival and prognosis of prostate cancer among the Iranian
male population.
2. Material and Method
In this cross-sectional study, data of patients with PCa was
collected from the Office of National Cancer registry in the
Ministry of Health and Medical Education (MOH&ME) for
the period of 2010-2015.
An additional telephone survey was conducted by trained in-
terviewers to collect data, including survival status, demo-
graphic characteristics, age of diagnosis, pathological find-
ings, and clinical profile. According to the study protocol,
three telephone calls within two consecutive weeks were
considered as a sufficient attempt to collect the data. For the
statistical analyses, the age at which the diagnosis took place
was categorized into five groups, including less than 50, 50-
59, 60-69, 70-79, and +80 years. Treatment types were cate-
gorized into surgery, radiotherapy, a combination of both, or
none. Using survival analysis set up, Kaplan-Meier survival
Figure 1: Kaplan-Meier estimates of survival in prostate cancer pa-
tients during 2010-15 in Iran.
rates were calculated according to demographic characteris-
tics, treatment type, and resident area. All the analyses were
done using STATA version 14 (StataCorp. 2015. Stata Statisti-
cal Software: Release 14. College Station, TX: StataCorp LP),
and probability values (P-values) less than 0.05 were consid-
ered statistically significant.
3. Results
Of 27,469 registered cases of PCa during 2010-15, data on
9,772 patients was gathered through the telephone survey
(overall response rate = 35%). The highest and lowest pro-
portions of cases belonged to Tehran (20%) and Sistan-
Balochestan (0.4%) provinces, respectively. Kaplan-Meier es-
timates showed that the overall five-year survival rate of PCa
was 82% (95%CI: 80-83%).
The five-year survival rate according to occupation was 88%
for farmers (95%CI: 85-91), 86% for government employees
(95%CI:80-90), 94% for those retired (95%CI: 92-96), and 90%
for patients with other occupations (95%CI: 89-92). As seen
from the results, retired PCa patients had significantly higher
survival compared to other categories (P-value:0.02).
The annual risk of death (per 1000 person-year at risk)
was highest amongst government employees (rate:88.9,
95%CI: 75.7,104.4) and lowest for retired patients (rate:75.12,
95%CI:68.7, 82). The risk was also highest for patients who re-
ceived no treatment (rate: 101.3, 95%CI:94.7, 108.4) and low-
est for those who received surgery (rate: 73.3, 95%CI: 67.5,
79.7). Furthermore, the risk was higher for urban dwellers
(rate: 76.6, 95%CI: 72.5,81) compared to those living in rural
areas (rate: 85.1, 95%CI: 72.5,81). The risk of death was also
highest in patients with elementary education level (mor-
tality rate: 81.9, 95%CI: 76.5, 87.8) and lowest in patients
with a bachelor’s degree (mortality rate: 67.9, 95%CI: 51.9,
88.9). The annual risk of death was highest for patients who
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Table 1: Five-Year survival rate of patients with prostate cancer according to general and clinical characteristics
Variable N (%) Number of failure 5-year survival (95%CI) Mortality rate (95%CI)
Age at diagnosis (years)
<50 242 (1.80) 4 0.7781 (0.635, 0.870) 93.02(67.10, 128.96)
50-59 1469 (10.91) 11 0.8156(0.769, 0.853) 91.78(80.65, 104.44)
60-69 3573 (26.53) 40 0.8134(0.784, 0.838) 92.09(84.76, 100.05)
70-79 4660 (34.61) 70 0.8119(0.787,0.833) 87.10(81.02, 93.63)
+80 3522 (26.15) 71 0.8461(0.820, 0.868) 81.39(74.96, 88.37)
Education
Illiterate 1,598(24.56) 72 0.8887(0.866,0.907) 77.02(70.95, 83.61)
Elementary 2,421(37.21) 62 0.9330(0.917,0.945) 81.97(76.51, 87.82)
Below high-school diploma 565(8.68) 12 0.9181(0.871,0.948) 76.96(65.06, 91.05)
High-school diploma-associate de-
gree
1,139(17.50) 22 0.8934(0.850,0.924) 79.56(68.77, 92.03)
Bachelors 539(8.28) 5 0.9111(0.830,0.954) 67.94(51.91, 88.94)
Masters or higher 245 (3.77) 5 0.8727(0.751,0.937) 72.96(52.13, 102.11)
Occupation
Retired 2870 (43.9) 33 0.9466(0.928,0.960) 75.12(68.76, 82.07)
Farmer 935 (14.3) 41 0.8878(0.858, 0.911) 80.30(72.55, 88.87)
Government employee 419 (6.41) 17 0.8608(0.806,0.901) 88.94(75.70, 104.49)
Other 2310 (35.3) 87 0.9096(0.891,0.924) 79.35(73.96, 85.13)
Resident area
Urban 5,238 (80.03) 144 0.9079(0.894,0.919) 85.19(78.16, 92.85)
Rural 1,307 (19.97) 35 0.9222(0.900,0.939) 76.68(72.57, 81.01)
Treatment type
Surgery+ Radiotherapy 1384 (10.1) 33 0.921(0.895,0.941) 85.56(77.44, 94.52)
Surgery 2841(20.9) 60 0.912(0.892,0.929) 73.39(67.53, 79.77)
Radiotherapy 1128 (8.3) 36 0.913(0.885,0.935) 86.12(77.75, 95.38)
No treatment 8230 (60.6) 67 0.675(0.648,0.700)) 101.36(94.70, 108.49)
were diagnosed earlier than the age of 50 (mortality rate: 93,
95%CI: 67.1-128.9) and lowest in patients who were diag-
nosed at the age of 80 or older (mortality rate: 81.4, 95%CI:
74.9, 88.3). The five-year survival rate according to the type
of treatment was 92% for the combination of radiotherapy
and surgery (95%CI: 89-94), 91% for radiotherapy (95%CI: 88-
93), 91% for surgery (95%CI: 89-92), and 67% for no treat-
ment (95%CI: 64-70). The survival rates of various types of
treatment did not differ significantly except for those who re-
ceived no treatment. (P-value<0.001).
The five-year survival rate in terms of the patients’ area of res-
idency showed that 90% of patients residing in urban setting
(95%CI: 89-91) and 92% of the patients residing in rural set-
ting (95%CI: 90-93) survived up to five years since diagno-
sis (P-value=0.006). The five-year survival rate according to
the patients’ level of education was 88% for illiterate patients
(95%CI:86-90), 93% for those who only completed elemen-
tary education (95%CI:91-94), 91% for patients with educa-
tion levels below high-school diploma (95%CI:87-94), 89%
for patients with associate degrees (95%CI:85-92), 91% for
patients with a bachelor’s degree (95%CI:83-95), and 87% for
patients with postgraduate and higher levels of academic ed-
ucation (95%CI:75-93). The log-rank tests showed no statis-
tically significant difference between survival of various ed-
ucation groups (P-Value = 0.06). The five-year survival rate
according to the age at which the diagnosis was carried out
was 77% for below 50 (95%CI: 63-87), 81% for 50-59 (95%CI:
76-85), 81% for 60-69 (95%CI:78-83), 81% for 70-79 (95%CI:
78-83), and 84% for above 80 years (95%CI: 82-86). There was
statistically significant difference between survival of various
age categories (P-value=0.203).
4. Discussion
This study concentrated on the factors that influence the
survival rate of prostate cancer, where receiving appropri-
ate treatment is one of the key factors. According to our
findings, there was no statistically significant difference be-
tween treatment options. However, untreated prostate can-
cer patients usually have more probability of death. There are
also studies in line with our findings indicating the positive
effects of treatment on recovery and survival from prostate
cancer. Kelly et.al stated that fatality of prostate cancer
has substantially decreased due to widespread treatment ad-
vances (27). Furthermore, a survey on frail elderly patients
with hormone-refractory prostate cancer concluded that the
treatment outcomes were similar (28).
In contrast, in a cohort study on hormonal therapy and radio-
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therapy field size, patients with intermediate-risk and high-
risk localized prostate cancers, neoadjuvant hormonal ther-
apy plus whole pelvic radiotherapy improved progression-
free survival compared with neoadjuvant hormonal therapy
plus prostate only radiotherapy and whole pelvic radiother-
apy plus adjuvant hormonal therapy at long-term follow-up
(29).
Also, a population-based study on localized prostate cancer
showed that the majority of patients with this condition un-
derestimated life expectancy without treatment, while over-
estimated life expectancy with surgery or radiation. These
expectations impacted their ability to make informed treat-
ment decisions, and may have resulted in overtreatment (30).
Employment status and patient’s job have demonstrated sig-
nificant influence on the survival rate in our study. Retired
patients had the highest survival rate, while government em-
ployees had the lowest. Various studies and pieces of evi-
dence also support our findings in suggesting that occupa-
tion is a considerable influence in the survival rate of prostate
cancer (31-33). Although a higher mortality rate was ob-
served in patients with lower levels of education, there was
no statistically significant correlation between survival and
education level. In saying that, studies suggest that patients
with higher education level have significantly lower mortality
rate (34, 35).
The mortality risk was higher for urban dwellers compared
to those living in rural areas. A systematic review suggests
that despite the presence of many variations in the evalua-
tion of geographical disturbance and mortality rate, people
in disadvantaged areas, and to a lesser extent more rural ar-
eas, face a greater prostate cancer burden (36). A statisti-
cally significant difference was observed in the survival rate
of various age groups. In fact, the mortality rate was higher
in patients with the diagnosis age of below 50. Some studies
support our findings and declare that younger men who have
lower grade cancer are more likely to be treated with prosta-
tectomy, while younger men with high grade and locally ad-
vanced prostate cancer have a poor prognosis compared to
elderlies (37). In contrast, another study suggests that elderly
patients are more likely to have high-risk prostate cancer at
diagnosis and are less likely to receive local therapy (38).
This is a retrospective study of this subject. Thereby, a num-
ber of key statistics could not be measured. There was no
access to the staging of patients. Thus, this important fac-
tor could not be investigated. We also did not have access
to a number of patients, and had instances where they did
not respond to our communication efforts, such as phone
calls. Considering the need for descriptive and epidemio-
logical studies on the prevalence and prognostic factors of
prostate cancer and its importance in health policymaking
and decision making, we recommend that the Ministry of
Health and health policymakers implement a detailed pa-
tient registration system. This can play an important role in
the various stages of prevention and treatment.
5. Conclusion
There are different factors in the prognosis and survival of
prostate cancer patients. Careful evaluation and thorough
understanding of these factors can play an important role in
how health policies and treatment choices are made. Regard-
ing the necessity of etiologic, prognostic, and epidemiologi-
cal studies, better access to the National Registry’s data on
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